Cancer Breast Cancer Diagnosis An Overview of Stage IV Breast Cancer By Lauren Evoy Davis Updated on February 16, 2022 Learn more</a>." data-inline-tooltip="true"> Medically reviewed Verywell Health articles are reviewed by board-certified physicians and healthcare professionals. Medical Reviewers confirm the content is thorough and accurate, reflecting the latest evidence-based research. Content is reviewed before publication and upon substantial updates. Learn more. by Doru Paul, MD Medically reviewed by Doru Paul, MD Doru Paul, MD, is triple board-certified in medical oncology, hematology, and internal medicine. He is an associate professor of clinical medicine at Weill Cornell Medical College and attending physician in the Department of Hematology and Oncology at the New York Presbyterian Weill Cornell Medical Center. Learn about our Medical Review Board Print Table of Contents View All Table of Contents Location of Metastases Staging Treatment Survival Rates Monitoring Coping Stage IV breast cancer (called metastatic cancer) is often diagnosed when cancer recurs, although it may sometimes be discovered at the initial diagnosis. Although metastatic breast cancer is not curable, treatment can help control the spread of the disease and help the person have a good quality of life. There are some people thriving with this chronic disease, including writer Katherine Russell Rich, author of The Red Devil. She found a breast lump and was diagnosed with stage IV breast cancer, which has a five-year survival rate of 29%. On a positive note, she survived 25 years with stage IV breast cancer. This article will give an overview of stage IV breast cancer, what it means for most people, how it's treated, and its outlook. Verywell / JR Bee Location of Metastases Stage IV breast cancer is diagnosed when cells from a primary tumor in the breast migrate to other parts of the body and establish one or more secondary tumors. Breast cancer can spread to nearly any organ of the body. The location of metastases can vary but tend to follow a similar pattern based on the cancer type. For example: Intraductal carcinoma most commonly spreads to the bones, liver, lungs, and brain. Lobular carcinoma tends to spread to the abdomen. Estrogen receptor-positive breast cancer most frequently spreads to bones. HER2-positive tumors are more likely to spread to the brain. Cancers metastasize at different times and speeds. For example, estrogen receptor-positive tumors tend to be around 3 centimeters (1.2 inches) in diameter before they metastasize. By contrast, HER2-positive tumor may be less than 1 centimeter (0.4 inches) before they spread to lymph nodes and beyond. For the purpose of classification and treatment, breast cancer that has spread to other parts of the body is still considered breast cancer regardless of its location. Breast cancer that spread to the lungs, for example, would not be referred to as lung cancer. Rather, it would be deemed breast cancer metastatic to the lungs. If you look at these cells under a microscope, they would be breast cancer cells, rather than lung cancer cells. Different Types of Metastatic Breast Cancer Breast Cancer Doctor Discussion Guide Get our printable guide for your next doctor's appointment to help you ask the right questions. Download PDF Email the Guide Send to yourself or a loved one. Sign Up This Doctor Discussion Guide has been sent to {{form.email}}. There was an error. Please try again. Staging Cancer staging is performed to direct treatment and predict the likely outcome, or prognosis. The staging system most commonly used for breast cancer—and most other cancers, for that matter—is called the TNM Classification of Malignant Tumors. In the TNM staging system: T refers to tumor size. N refers to the number of lymph nodes affected by cancer. M refers to metastasis. The letters are followed by numbers to either characterize the size of the tumor (for example, T1 for a small tumor and T3 for a bigger tumor) or the extent of a malignancy (with N0 meaning no affected lymph nodes and N4 meaning 10 or more affected lymph nodes). Regarding the "M" classification, you can either be M0 (no metastasis) or M1 (metastasis). There are no in-betweens. Therefore, you can be any T or N classification and still be considered stage IV if metastasis is confirmed. Metastatic breast cancers are not all treated the same. The diagnosis would also include an assessment of the tumor location, tumor grade, tumor size, hormone receptor status, HER2 status, and many other factors, each of which directs the ultimate course of treatment. Understanding Your Breast Tumor Size and Stage How Is Stage IV Breast Cancer Treated? The general aim of stage IV cancer treatment is to improve the quality of life and extend the duration of life of patients. Each person will be treated differently based on the disease characteristics and the intended goals of treatment. Most treatments aim at decreasing the tumor burden and stabilizing the disease. In general, stage IV cancer treatments, although they may extend life in a significant number of patients, are considered palliative (meant to relieve disease burden) because only a handful of treated patients are cured of their disease. Systemic Therapy For those who decide to pursue treatment, systemic therapies (those that administer treatment throughout the body) are commonly used. These include: Hormonal therapy, including tamoxifen, aromatase inhibitors, and Faslodex (fulvestrant) Targeted therapy, like Herceptin (trastuzumab) and Perjeta (pertuzumab) Chemotherapy Immunotherapy, namely Keytruda (pembrolizumab), which is used in combination with chemotherapy to treat advanced triple-negative breast cancer expressing the protein PD-L1. A combination of therapies may be used, either together or in stages. Treatment staging involves using a drug until the side effects become intolerable or the cancer starts to grow again. If this happens, the first-line drug will be switched with a second-line drug, and so on. Drug Selection The choice of systemic therapy is largely based on one's hormone receptor status (an indication of whether the hormones estrogen or progesterone affect the growth of a tumor) and/or HER2 status (whether a particular gene influences tumor growth). A positive status means that receptors for these substances have been detected on cancer cells, while a negative status means that no receptors were found. Cancer cells obtained through biopsy or surgery are used by pathologists to determine this. Based on these evaluations, the oncologist will typically recommend the following treatments: Hormone receptor-positive cancers are often treated with hormone therapy, such as tamoxifen or an aromatase inhibitor. This may be combined with a targeted drug such as Afinitor (everolimus), Ibrance (palbociclib), Kisqali (ribociclib), or Verzenzio (abemaciclib). Hormone receptor-negative cancers are typically treated with chemo. HER2-positive cancers may benefit from the targeted drug Herceptin when used in combination with chemo, hormonal therapy, or other HER2 medications. HER2-negative cancers are typically treated with chemo. Hormone therapy may be added if the cancer is hormone receptor-positive. The targeted drug Lynparza (olaparib) is sometimes staged after chemo for people with BRCA1 or BRCA2 gene mutations. Radiation and Surgery In addition to systemic therapies, radiation and surgery may be helpful in specific circumstances. With radiation especially, the goal may be therapeutic (to slow the progression of the disease) or palliative (to provide comfort by reducing the tumor size). Among the examples of how these treatments are used: Bone metastases often benefit from radiation to reduce pain and prevent bone fracture. In addition, bone-modifying drugs like Zometa (zoledronic acid) can reduce the risk of cancer-related bone loss (osteoporosis). Lung metastases are sometimes treated with surgery if the spread of cancer is limited. A specialized form of radiation therapy known as stereotactic body radiotherapy (SBRT) may also be considered. Brain metastases may also be treated with surgery or SBRT if only a single or few metastases are found. Liver metastases may be treated with radiation, SBRT, or surgery to prevent blood vessel blockage in the liver. Spinal metastases are typically treated with SBRT or surgery to prevent the compression of the spinal cord. Radiation can also shrink tumors that have penetrated the skin and caused an open wound on the breast or chest. Because current treatments are unlikely to cure metastatic breast cancer, you may want to take part in a clinical trial to try newer treatments if you are in good health. Treatment Options for Metastatic Breast Cancer Survival Rates The five-year survival rate for stage IV breast cancer is 29%, which means that 29 of 100 women will live for at least five years. Some will live far longer, while others will live less. The median life expectancy is three years. As distressing as this may seem, the figures do not differentiate between the number of women who decide to be treated versus those who don't. As such, you should not assume that having stage IV breast cancer means that you have three to five years to live. Some women will live more than 10 years. A number of factors are known to influence survival, including: AgeHealth at the time of the diagnosisCancer stage at the time of diagnosisLocation and extent of the metastasesHER2 or hormone-receptor statusWhether the cancer has recurredTreatments previously used It is important to remember that these survival statistics are derived from a large population of women, each of whom had individual circumstances. Moreover, as newer and more effective treatments are being developed, the survival rate five years from now may be very different than today. How Long Can You Live With Stage 4 Breast Cancer? Monitoring While the goal of early-stage cancer treatment is to eliminate the malignancy and put the cancer into remission, the goals associated with stage IV cancer are different. The primary aim is to keep the cancer from spreading, which requires ongoing monitoring. The tool most commonly used for this is an imaging technique known as a positron emission tomography/computed tomography (PET/CT) scan. It involves PET technology, which looks at cell activity, and CT technology, which uses X-rays to create 3-D images of tissue to measure tumor size and disease progression. Other techniques, like magnetic resonance imaging (MRI) and dual-energy X-ray absorptiometry (DEXA), may be used to monitor certain soft tissue or bone malignancies, respectively. Serial blood tumor markers are also used to monitor disease status. These are blood tests that detect substances, referred to as tumor markers, that increase as cancer either spreads or advances. Examples include the tumor markers CA 15-3 and CA 27-29, which are elevated in more than 70% of people with metastatic breast cancer. Disease Progression While systemic treatment may keep the cancer stable for months or years, there may be times when it becomes unstable and starts to progress. When this happens, a change of treatment can often stabilize the malignancy. Generally speaking, doctors will start with hormonal therapy (if hormone receptor-positive) or targeted therapy (if HER2-positive), changing individual agents if one starts to fail. If these no longer work, chemotherapy will be used. However, each time that cancer progresses during chemo, the chances of the new drug working get lower. It is at this stage that palliative care made be considered. 6:12 Coping With Stage IV Breast Cancer It is natural to feel depressed, anxious, or even angry when you have been diagnosed with stage IV breast cancer. It can leave you feeling as if you have no control over your health or future. Moreover, you may find that certain people will withdraw from you or suggest that you have metastatic cancer because you "left it too late." It is important to shield yourself from these negative emotions and embrace those who can provide you with genuine support. These include loved ones, support groups, and your oncology team. If you are unable to cope, ask for a referral to a therapist who can provide you counseling or a psychiatrist able to dispense treatment. With that being said, there are women who experience positive emotional growth after being diagnosed with stage IV breast cancer. It is not uncommon to hear someone say that cancer helped prioritize their life, allowing them to pursue what is truly important and connect with people on a deeper, more profound level. Whatever your experience, don't go it alone. Seek support and work with your medical team as a full partner in your care. Summary Stage IV breast cancer is also known as metastatic breast cancer, meaning the cancer has spread to other organs. While stage IV breast cancer is not considered curable, treatments can control the spread and improve quality of life in many cases. The median survival is three years, but some people live 10 years or more after diagnosis. Treatments can include chemotherapy, radiation, surgery, hormone therapy, and targeted therapy. A Word From Verywell Stage IV breast cancer can seem daunting but more and more people are living with this as a chronic illness, especially with the speed of newer therapies. If you feel unwell as a result of your cancer or your therapies, seek help from your medical team right away. Frequently Asked Questions Can stage IV breast cancer be detected on a mammogram? The primary tumor may be detected on a mammogram, but other testing would be necessary to tell if the cancer has spread to other parts of the body. In some cases, the metastases (other tumor sites) are discovered first. Some aggressive forms of breast cancer are not detected readily by a mammogram. What is the prognosis for stage IV breast cancer? The five-year-survival rate for stage IV breast cancer is 29%. However some people live with this chronic illness for many years. How to Find a Metastatic Breast Cancer Support Group Originally written by Pam Stephan Pam Stephan Pam Stephan is a breast cancer survivor. Learn about our editorial process Was this page helpful? Thanks for your feedback! Get honest information, the latest research, and support for you or a loved one with breast cancer right to your inbox. Sign Up You're in! Thank you, {{form.email}}, for signing up. There was an error. Please try again. What are your concerns? Other Inaccurate Hard to Understand Submit 8 Sources Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Susan G. Komen. Understand breast cancer survival rates. Gerratana L, Fanotto V, Bonotto M, et al. Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis. 2015;32(2):125-133. doi:10.1007/s10585-015-9697-2. Westphal T, Gampenrieder SP, Rinnerthaler G, Greil R. Cure in metastatic breast cancer. Memo. 2018;11(3):172-179. doi:10.1007/s12254-018-0426-9 Food and Drug Administration. Highlights of prescribing information: Keytruda (pembrolizumab) injection. Gao RW, Edlund S, Yuan J. Dramatic regression of a fungating breast lesion treated with radiation therapy. Cureus. 2017;9(6):e1360. doi:10.7759/cureus.1360 Mariotto A, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26(6):809-815. doi:10.1158/1055-9965.epi-16-0889 Fedele P, Ciccarese M, Surico G, Cinieri S. An update on first line therapies for metastatic breast cancer. Expert Opin Pharmacother. 2018;19(3):243-252. doi:10.1080/14656566.2018.1425680 Oregon Health & Science University, Oregon State University, Understanding the aggressive breast cancers missed by mammogram screening. Additional Reading Liedtke C, Kolberg H. Systemic therapy of advanced/metastatic breast cancer—current evidence and future concepts. Breast Care. 2016;11(4):275-81. doi:10.1159/000447549 Noone A, Howlader N, Krapcho M, et al (eds). SEER Cancer Statistics Review. National Cancer Institute. Riedl CC, Pinker K, Ulaner GA, et al. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Med Imaging. 2017;44(9):1428-37. doi:10.1007/s00259-017-3703-7 Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108-21. doi:10.1056/NEJMoa1809615